Fieldpoint Private Securities’s SpringWorks Therapeutics SWTX Stock Holding History

Fieldpoint Private Securities’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$40K	Sell	1,615 -4	-0.2%	-$146	0.01%	526
2022 Q1	$91K	Hold	1,619	–	–	0.02%	452
2021 Q4	$100K	Buy	1,619 +819	+102%	+$54.2K	0.02%	443
2021 Q3	$51K	Hold	800	–	–	0.01%	576
2021 Q2	$60K	Buy	+800	New	+$60.7K	0.01%	533

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fieldpoint Private Securities's SWTX Position: Q2 2022 in Review

Fieldpoint Private Securities reduced its SpringWorks Therapeutics (SWTX) stake by 0.25% in Q2 2022, selling an estimated $146 and leaving 1,615 shares worth $40K. The position accounts for 0.01% of the portfolio, ranked #526.

Fieldpoint Private Securities first reported a position in SWTX in Q2 2021 and has held it in 5 quarters since. The position peaked at $100K in Q4 2021. 143 funds tracked by Wall St. Rank hold SWTX as of Q2 2022.

Fieldpoint Private Securities held 1,615 shares of SpringWorks Therapeutics worth $40K as of Q2 2022.
Fieldpoint Private Securities sold 4 SpringWorks Therapeutics shares in Q2 2022, an estimated $146.
SpringWorks Therapeutics made up 0.01% of Fieldpoint Private Securities's portfolio in Q2 2022, its #526 holding.
Fieldpoint Private Securities first reported a position in SpringWorks Therapeutics in Q2 2021 and has held it in 5 quarters since.
Fieldpoint Private Securities's SpringWorks Therapeutics position peaked at $100K in Q4 2021.
143 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.